Oncolytic virus therapy: A new era of cancer treatment at dawn

A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC).

(2017) Allyson J. Ocean et al.   JOURNAL OF CLINICAL ONCOLOGY

Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer

(2016) Robert Coffin   Immunotherapy

MP13-19 A PHASE II/III TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-REFRACTORY NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)

(2016) Vignesh T. Packiam et al.   JOURNAL OF UROLOGY

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses

(2016) Karishma Rajani et al.   MOLECULAR THERAPY

Treatment of Human Thyroid Carcinoma Cells with the G47delta Oncolytic Herpes Simplex Virus

(2015) Jia-Ni Wang et al.   Asian Pacific Journal of Cancer Prevention

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy

(2015) Kevin J Harrington et al.   Expert Review of Anticancer Therapy

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Going viral: a review of replication-selective oncolytic adenoviruses

(2015) Christopher Larson et al.   Oncotarget

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta

(2014) Jiani Wang et al.   Cancer Cell International

A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma

(2014) D. W. Sborov et al.   CLINICAL CANCER RESEARCH

Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy

(2014) Stephen J. Russell et al.   MAYO CLINIC PROCEEDINGS

Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults

(2014) Kimberly P Kicielinski et al.   MOLECULAR THERAPY

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus

(2014) Slawomir Antoszczyk et al.   NEURO-ONCOLOGY

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model

(2013) T. A. Cheema et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

(2012) E. M. Karapanagiotou et al.   CLINICAL CANCER RESEARCH

Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress

(2012) Balveen Kaur et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhancedin vivoantitumor effect against human gastric cancer

(2012) Toshiaki Tsuji et al.   INTERNATIONAL JOURNAL OF CANCER

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

(2012) James M. Burke et al.   JOURNAL OF UROLOGY

Abstract C22: A phase II study of intravenous wild-type reovirus (Reolysin(R)) in combination with paclitaxel plus carboplatin in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

(2012) A. B. Karnad et al.   MOLECULAR CANCER THERAPEUTICS

Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

(2012) Evanthia Galanis et al.   MOLECULAR THERAPY

Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients

(2012) R. A. Adair et al.   Science Translational Medicine

Abstract 2594: Reovirus replication in ovarian and peritoneal tumors after intravenous administration

(2011) Mitch A. Phelps et al.   CANCER RESEARCH

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

(2011) Kelley A Parato et al.   MOLECULAR THERAPY

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma

(2011) Jia-Ni Wang et al.   Chinese Journal of Cancer

Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic

(2010) C. M. Thirukkumaran et al.   CANCER RESEARCH

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors

(2009) Radharani Gollamudi et al.   INVESTIGATIONAL NEW DRUGS

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

(2008) C L White et al.   GENE THERAPY

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY

Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16

(2008) M Aghi et al.   ONCOGENE